Vicki L. Sato - Mar 15, 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Mar 15, 2024
Transactions value $
-$33,487
Form type
4
Date filed
3/19/2024, 04:27 PM
Previous filing
Feb 20, 2024
Next filing
Apr 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$33.5K -1.67K -1.37% $20.10 120K Mar 15, 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.72 to $20.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 4,216 unvested RSUs.